MXPA04007193A - Uso de alquilfosfocolinas para el tratamiento preventivo de enfermedades protozoicas. - Google Patents
Uso de alquilfosfocolinas para el tratamiento preventivo de enfermedades protozoicas.Info
- Publication number
- MXPA04007193A MXPA04007193A MXPA04007193A MXPA04007193A MXPA04007193A MX PA04007193 A MXPA04007193 A MX PA04007193A MX PA04007193 A MXPA04007193 A MX PA04007193A MX PA04007193 A MXPA04007193 A MX PA04007193A MX PA04007193 A MXPA04007193 A MX PA04007193A
- Authority
- MX
- Mexico
- Prior art keywords
- active ingredient
- use according
- dose
- leishmaniasis
- hexadecylphosphocholine
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 21
- 201000010099 disease Diseases 0.000 title claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 11
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 claims abstract description 69
- 229960003775 miltefosine Drugs 0.000 claims abstract description 69
- 208000004554 Leishmaniasis Diseases 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 5
- 239000010452 phosphate Substances 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims description 32
- 230000003449 preventive effect Effects 0.000 claims description 16
- 230000003474 anti-emetic effect Effects 0.000 claims description 9
- 239000002111 antiemetic agent Substances 0.000 claims description 9
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 claims description 9
- 206010047505 Visceral leishmaniasis Diseases 0.000 claims description 8
- 230000001142 anti-diarrhea Effects 0.000 claims description 8
- 229950010632 perifosine Drugs 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 201000000626 mucocutaneous leishmaniasis Diseases 0.000 claims description 4
- 230000009278 visceral effect Effects 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- SZFPYBIJACMNJV-UHFFFAOYSA-O (1,1-dimethylpiperidin-1-ium-4-yl) octadecyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-O 0.000 claims 3
- 206010011668 Cutaneous leishmaniasis Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 32
- 239000003795 chemical substances by application Substances 0.000 description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 230000002354 daily effect Effects 0.000 description 11
- 239000000945 filler Substances 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 238000011049 filling Methods 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- 239000007938 effervescent tablet Substances 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 239000010419 fine particle Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 229940125683 antiemetic agent Drugs 0.000 description 2
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 235000019691 monocalcium phosphate Nutrition 0.000 description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- KSEYRUGYKHXGFW-UHFFFAOYSA-N 6-methoxy-N-[(1-prop-2-enyl-2-pyrrolidinyl)methyl]-2H-benzotriazole-5-carboxamide Chemical compound COC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C KSEYRUGYKHXGFW-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229960003687 alizapride Drugs 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Chemical class 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- ZDINGUUTWDGGFF-UHFFFAOYSA-N antimony(5+) Chemical class [Sb+5] ZDINGUUTWDGGFF-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 229940054066 benzamide antipsychotics Drugs 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical compound CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Chemical class 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 239000003063 flame retardant Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- YQDGWZZYGYKDLR-UZVLBLASSA-K sodium stibogluconate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].O1[C@H]([C@H](O)CO)[C@H](O2)[C@H](C([O-])=O)O[Sb]21([O-])O[Sb]1(O)(O[C@H]2C([O-])=O)O[C@H]([C@H](O)CO)[C@@H]2O1 YQDGWZZYGYKDLR-UZVLBLASSA-K 0.000 description 1
- 229960001567 sodium stibogluconate Drugs 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000037972 tropical disease Diseases 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10203195A DE10203195A1 (de) | 2002-01-25 | 2002-01-25 | Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen |
| PCT/EP2003/000072 WO2003061669A1 (de) | 2002-01-25 | 2003-01-07 | Verwendung von alkylphosphocholinen in der präventivbehandlung von protozoenerkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04007193A true MXPA04007193A (es) | 2004-10-29 |
Family
ID=7713213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04007193A MXPA04007193A (es) | 2002-01-25 | 2003-01-07 | Uso de alquilfosfocolinas para el tratamiento preventivo de enfermedades protozoicas. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1467742A1 (https=) |
| JP (1) | JP2005515244A (https=) |
| CN (1) | CN1622811A (https=) |
| AR (1) | AR038224A1 (https=) |
| AU (1) | AU2003236787B2 (https=) |
| BR (1) | BR0307021A (https=) |
| CA (1) | CA2470185A1 (https=) |
| CO (1) | CO5601024A2 (https=) |
| DE (1) | DE10203195A1 (https=) |
| IL (2) | IL162492A0 (https=) |
| MX (1) | MXPA04007193A (https=) |
| NZ (1) | NZ548040A (https=) |
| PE (1) | PE20030732A1 (https=) |
| TW (1) | TWI339582B (https=) |
| WO (1) | WO2003061669A1 (https=) |
| ZA (1) | ZA200404690B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT501545B1 (de) * | 2005-02-23 | 2007-10-15 | Obwaller Andreas Dr | Reinigungsmittel für kontaktlinsen |
| CA2632449A1 (en) * | 2005-12-19 | 2007-06-28 | Aeterna Zentaris Gmbh | Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof |
| EP1800684A1 (en) * | 2005-12-20 | 2007-06-27 | Zentaris GmbH | Novel alkyl phospholipid derivatives and uses thereof |
| CN104473941A (zh) * | 2014-12-20 | 2015-04-01 | 长沙佰顺生物科技有限公司 | 一种含有米替福新的药物制剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4132345A1 (de) * | 1991-09-27 | 1993-04-01 | Max Planck Gesellschaft | Ether-lysolecithine und alkylphosphocholine in liposomen |
| DE4132344A1 (de) * | 1991-09-27 | 1993-04-01 | Max Planck Gesellschaft | Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis |
| BR9306040A (pt) * | 1992-03-06 | 1997-11-18 | Statens Seruminstitut | Tratamento e profilaxia de doenças provocadas por parasitos ou bactérias |
| ES2175663T3 (es) * | 1998-01-22 | 2002-11-16 | Zentaris Ag | Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis. |
| DE10020812C2 (de) * | 2000-04-20 | 2003-06-26 | Robert Koch Inst | Verwendung von Naphthindazol-4,9-chinonen als Antiparasitika |
| AU2002232400A1 (en) * | 2000-11-06 | 2002-05-15 | U.S. Army Medical Research And Materiel Command | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis |
-
2002
- 2002-01-25 DE DE10203195A patent/DE10203195A1/de not_active Withdrawn
-
2003
- 2003-01-07 IL IL16249203A patent/IL162492A0/xx unknown
- 2003-01-07 CN CNA038027062A patent/CN1622811A/zh active Pending
- 2003-01-07 CA CA002470185A patent/CA2470185A1/en not_active Abandoned
- 2003-01-07 EP EP03731619A patent/EP1467742A1/de not_active Ceased
- 2003-01-07 JP JP2003561613A patent/JP2005515244A/ja active Pending
- 2003-01-07 AU AU2003236787A patent/AU2003236787B2/en not_active Expired
- 2003-01-07 MX MXPA04007193A patent/MXPA04007193A/es active IP Right Grant
- 2003-01-07 WO PCT/EP2003/000072 patent/WO2003061669A1/de not_active Ceased
- 2003-01-07 NZ NZ548040A patent/NZ548040A/en not_active IP Right Cessation
- 2003-01-07 BR BR0307021-2A patent/BR0307021A/pt not_active Application Discontinuation
- 2003-01-13 TW TW092100614A patent/TWI339582B/zh not_active IP Right Cessation
- 2003-01-20 PE PE2003000061A patent/PE20030732A1/es not_active Application Discontinuation
- 2003-01-24 AR ARP030100214A patent/AR038224A1/es unknown
-
2004
- 2004-06-14 ZA ZA200404690A patent/ZA200404690B/en unknown
- 2004-06-14 IL IL162492A patent/IL162492A/en active IP Right Grant
- 2004-07-23 CO CO04070642A patent/CO5601024A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ548040A (en) | 2007-06-29 |
| TW200302103A (en) | 2003-08-01 |
| BR0307021A (pt) | 2004-11-03 |
| AR038224A1 (es) | 2005-01-05 |
| JP2005515244A (ja) | 2005-05-26 |
| IL162492A0 (en) | 2005-11-20 |
| TWI339582B (en) | 2011-04-01 |
| IL162492A (en) | 2009-12-24 |
| EP1467742A1 (de) | 2004-10-20 |
| ZA200404690B (en) | 2004-09-27 |
| CA2470185A1 (en) | 2003-07-31 |
| AU2003236787B2 (en) | 2007-03-22 |
| PE20030732A1 (es) | 2003-09-27 |
| CN1622811A (zh) | 2005-06-01 |
| WO2003061669A1 (de) | 2003-07-31 |
| DE10203195A1 (de) | 2003-08-07 |
| CO5601024A2 (es) | 2006-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100329249B1 (ko) | 경비 투여 가능한 조성물 | |
| EP0306060B1 (en) | Pharmaceutical products providing enhanced analgesia | |
| DK174916B1 (da) | Farmaceutisk sammensætning og fremgangsmåde til at stabilisere denne | |
| EP0282132A2 (en) | Compositions and their use for treating gastrointestinal disorders | |
| JPH026409A (ja) | ジホスホン酸誘導体経口医薬組成物 | |
| EP3003383B1 (en) | Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d | |
| CN100413492C (zh) | 口服给药治疗利什曼病的含有米替福星的固体药物组合物 | |
| JP2859318B2 (ja) | イノシトールトリホスフェートを含有する骨疾患に対する医薬 | |
| JPS61275220A (ja) | 新規薬学的組成物 | |
| US7887817B2 (en) | Process for preventing protozoal diseases | |
| MXPA04007193A (es) | Uso de alquilfosfocolinas para el tratamiento preventivo de enfermedades protozoicas. | |
| US3196078A (en) | Process for combating retinits pigmentosa | |
| KR20010080765A (ko) | 약제학적 제제 | |
| JP3542801B2 (ja) | パーキンソン病治療剤 | |
| HK1077217A (en) | Use of alkylphosphocholines for the preventative treatment of protozoan diseases | |
| RU2174836C1 (ru) | Фармацевтическая композиция, обладающая анальгезирующим действием | |
| RU2190390C2 (ru) | Твердая фармацевтическая композиция для орального введения при лечении лейшманиоза и способ ее производства, фармацевтическая комбинация для лечения лейшманиоза у млекопитающих и способ лечения (варианты) | |
| KR950005869B1 (ko) | 위염 치료제 | |
| US3584126A (en) | Anthelmintic method employing phosphonate derivative | |
| US5238946A (en) | Therapeutic agent for gastritis | |
| EP0254068A2 (en) | Novel therapeutic agent for gastritis | |
| BG64968B1 (bg) | Твърди фармацевтични състави, съдържащи милтефозин за орално приложение при лечението на leishmaniasis | |
| RU2000122308A (ru) | Твердая фармацевтическая композиция для орального введения при лечении лейшманиоза и способ ее производства, фармацевтическая комбинация для лечения лейшманиоза у млекопитающих и способ лечения (варианты) | |
| JPS63201125A (ja) | 胃十二指腸潰瘍の治療に対する相乗的抗分泌作用を有する薬剤組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |